MX2012008391A - Derivados de piridina di-sustituida como agentes anticancer. - Google Patents

Derivados de piridina di-sustituida como agentes anticancer.

Info

Publication number
MX2012008391A
MX2012008391A MX2012008391A MX2012008391A MX2012008391A MX 2012008391 A MX2012008391 A MX 2012008391A MX 2012008391 A MX2012008391 A MX 2012008391A MX 2012008391 A MX2012008391 A MX 2012008391A MX 2012008391 A MX2012008391 A MX 2012008391A
Authority
MX
Mexico
Prior art keywords
sub
phenylene
lower alkylene
optionally substituted
anticancers
Prior art date
Application number
MX2012008391A
Other languages
English (en)
Inventor
Keisuke Miyajima
Takashi Suzuki
Satoshi Yamada
Kazuhisa Sugiyama
Kazuo Sekiguchi
Takumi Sumida
Hideki Takasu
Yutaka Kojima
Mitsuhiro Okuno
Yasuo Yanagihara
Shigekazu Fujita
Hideo Tanaka
Shinya Ohtsuka
Toshiyuki Hirose
Yosuke Sato
Koji Sakai
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2012008391A publication Critical patent/MX2012008391A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención proporciona un nuevo compuesto que tiene excelente efecto antitumoral. El compuesto de la presente invención se representa por la siguiente fórmula general (1) en donde R1 y R2 son arilo o similar; A es alquileno inferior, el anillo X es arileno opcionalmente sustituido, E es un enlace o alquenileno inferior; el anillo Y es heterocicloalquileno opcionalmente sustituido que contiene uno o más átomos de nitrógeno, uno de los cuales está unido al grupo carbonilo adyacente; G es -NH-N (alquilo inferior)-G2-, -NH-CH2-G2-, -N (alquilo inferior) -CH2-G2- o -CH2-G2-, [en donde G2 se une a R2, G2-R2 es enlace-R2, fenileno-G3-R2, fenileno-G4-O-R2, fenileno-G5-NH-R2, fenileno-G6-N (alquilo inferior)-R2 o quinolinadiilo-O-R2, el fenileno de los grupos que contienen fenileno está opcionalmente sustituido con uno o más sustituyentes; G3-R2 es -0-alquileno inferior-R2, o similar, G4-O- es alquileno inferior-O-, o similar; G5 es alquileno inferior y G6 es alquileno inferior).
MX2012008391A 2010-01-29 2011-01-28 Derivados de piridina di-sustituida como agentes anticancer. MX2012008391A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29963110P 2010-01-29 2010-01-29
US35972910P 2010-06-29 2010-06-29
PCT/JP2011/052302 WO2011093524A1 (en) 2010-01-29 2011-01-28 Di - substituted pyridine derivatives as anticancers

Publications (1)

Publication Number Publication Date
MX2012008391A true MX2012008391A (es) 2012-08-15

Family

ID=43797869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008391A MX2012008391A (es) 2010-01-29 2011-01-28 Derivados de piridina di-sustituida como agentes anticancer.

Country Status (27)

Country Link
US (1) US8722663B2 (es)
EP (1) EP2528897B9 (es)
JP (1) JP5335932B2 (es)
KR (1) KR101411030B1 (es)
CN (1) CN102791690B (es)
AR (1) AR080057A1 (es)
AU (1) AU2011211306B2 (es)
CA (1) CA2788073A1 (es)
CO (1) CO6561817A2 (es)
DK (1) DK2528897T3 (es)
EA (1) EA026042B1 (es)
ES (1) ES2521016T3 (es)
HK (1) HK1178523A1 (es)
HR (1) HRP20141190T1 (es)
IL (1) IL221146A (es)
MX (1) MX2012008391A (es)
MY (1) MY160875A (es)
NZ (1) NZ601794A (es)
PL (1) PL2528897T3 (es)
PT (1) PT2528897E (es)
RS (1) RS53705B1 (es)
SG (1) SG182663A1 (es)
SI (1) SI2528897T1 (es)
SM (1) SMT201500007B (es)
TW (1) TWI404713B (es)
UA (1) UA107692C2 (es)
WO (1) WO2011093524A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013047223A (ja) * 2011-07-28 2013-03-07 Otsuka Pharmaceut Co Ltd 医薬
EP2970205B1 (en) 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
EP3036222A2 (en) * 2013-08-23 2016-06-29 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2826443T3 (es) * 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
TW201702232A (zh) 2015-04-10 2017-01-16 亞瑞克西斯製藥公司 經取代之喹唑啉化合物及其使用方法
CA2982360A1 (en) 2015-04-15 2016-10-20 Liansheng Li Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2018068017A1 (en) 2016-10-07 2018-04-12 Araxes Pharma Llc Heterocyclic compounds as inhibitors of ras and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
BR112019024674A2 (pt) 2017-05-25 2020-06-16 Araxes Pharma Llc Inibidores covalentes da kras
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
CN112812781B (zh) * 2021-01-21 2023-09-29 西安瑞联新材料股份有限公司 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法
CN116903587B (zh) * 2023-06-01 2024-03-22 三峡大学 一种角鲨烯环氧酶抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301880A (ja) * 1985-09-03 1988-12-08 Otsuka Pharmaceut Co Ltd ５−フルオロウラシル誘導体
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
US6262088B1 (en) * 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2001089450A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
JP2002226429A (ja) * 2001-02-06 2002-08-14 Fuji Photo Film Co Ltd アクリル酸エステル化合物の製造方法
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
EP1773797A2 (en) 2004-08-06 2007-04-18 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
ES2463450T3 (es) 2005-12-05 2014-05-28 Otsuka Pharmaceutical Co., Ltd. Fármaco medicinal
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
US20100136509A1 (en) 2007-07-02 2010-06-03 Alden Mejer System and method for clinical trial investigator meeting delivery and training including dynamic media enrichment
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
DE202009007345U1 (de) * 2009-05-22 2009-09-10 Schebo (R) . Biotech Ag Neue Pharmazeutika und Arzneimittelzubereitungen

Also Published As

Publication number Publication date
EP2528897B9 (en) 2015-09-09
JP5335932B2 (ja) 2013-11-06
KR101411030B1 (ko) 2014-06-30
PT2528897E (pt) 2014-11-12
DK2528897T3 (en) 2014-12-08
US20120283242A1 (en) 2012-11-08
TW201136912A (en) 2011-11-01
EP2528897B1 (en) 2014-10-15
US8722663B2 (en) 2014-05-13
SMT201500007B (it) 2015-03-05
HK1178523A1 (en) 2013-09-13
EA026042B1 (ru) 2017-02-28
CN102791690B (zh) 2015-12-02
KR20120065268A (ko) 2012-06-20
MY160875A (en) 2017-03-31
WO2011093524A1 (en) 2011-08-04
AU2011211306A1 (en) 2012-08-16
NZ601794A (en) 2014-04-30
ES2521016T3 (es) 2014-11-12
JP2012525324A (ja) 2012-10-22
AU2011211306B2 (en) 2016-07-07
AR080057A1 (es) 2012-03-07
CN102791690A (zh) 2012-11-21
SG182663A1 (en) 2012-08-30
RS53705B1 (en) 2015-04-30
SI2528897T1 (sl) 2015-02-27
TWI404713B (zh) 2013-08-11
WO2011093524A9 (en) 2011-12-01
CA2788073A1 (en) 2011-08-04
PL2528897T3 (pl) 2015-03-31
CO6561817A2 (es) 2012-11-15
EA201290720A1 (ru) 2013-02-28
HRP20141190T1 (hr) 2015-01-30
EP2528897A1 (en) 2012-12-05
IL221146A (en) 2015-11-30
UA107692C2 (uk) 2015-02-10

Similar Documents

Publication Publication Date Title
MX2012008391A (es) Derivados de piridina di-sustituida como agentes anticancer.
CY1117157T1 (el) Υποκατεστημενο παραγωγο ισοκινολινης
CY1114452T1 (el) Ενωσεις πυρρολιου
MY156962A (en) Fuel compositions
DE502008001409D1 (de) Bisamid-zinkbasen
ECSP12012212A (es) Derivados de ariletinilo
MY169814A (en) Diesel fuel compositions
UY31232A1 (es) Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
IN2012DN03129A (es)
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
IN2014CN03976A (es)
MY148482A (en) Heterocyclic compound and pharmaceutical composition thereof
MY159870A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
IN2014CN02843A (es)
MY161134A (en) Piperazine compound having a pgds inhibitory effect
MY142304A (en) Novel pyrimidine nucleoside compound or salt thereof
GB2470170A (en) Dithienothiophene derivatives
MY161992A (en) Novel tetrahydroisoquinoline derivative
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
PH12014502108A1 (en) Polyamide compositions with improved optical properties
WO2010079499A3 (en) Novel hydrazide containing taxane conjugates
EA201390323A1 (ru) Производные 4-(метиламинофенокси)пиридин-3-илбензамида для лечения рака
SA515360302B1 (ar) مركبات رباعي أكسا ثنائي فوسفا سبيرو
MA32342B1 (fr) Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG166757A1 (en) Thermoplastic polymer composition and production method thereof

Legal Events

Date Code Title Description
FG Grant or registration